Deals
Novartis Sues Teva to Block Generic Form of Transplant Drug
This article is for subscribers only.
Novartis AG, Europe’s second-biggest drugmaker by sales, sued Teva Pharmaceutical Industries Ltd. in a U.S. court alleging infringement of patents for Myfortic, used to help prevent organ rejection in kidney transplant patients.
Teva has applied to the U.S. Food and Drug Administration for permission to market copies of delayed-release Myfortic before the three Novartis patents expire, Novartis said in a complaint filed today in federal court in Wilmington, Delaware.